Hepatic injury following feprazone therapy.
Two cases of feprazone-induced hepatic injury are reported. Both patients developed jaundice within one month of commencing therapy. Histological investigation showed a granulomatous reaction in one case and hepatitic changes in the other. The changes were similar to those seen as a complication of phenylbutazone therapy. When the administration of feprazone was discontinued both the clinical and biochemical changes were resolved.
D000328:Adult; D000368:Aged; D001416:Back Pain / Q000188:drug therapy; D005260:Female; D011298:Feprazone / Q000009:adverse effects*; D006801:Humans; D007565:Jaundice / Q000139:chemically induced*; D007592:Joint Diseases / Q000188:drug therapy; D008099:Liver / Q000187:drug effects; D008297:Male; D010653:Phenylbutazone / Q000031:analogs & derivatives*
D011298:Feprazone; D010653:Phenylbutazone